September 2019 Issue - Endovascular Today

Table of Contents

Issue

September 2019

Paclitaxel In PAD

Applying What We've Learned Since the Meta-Analysis

Supplement

Dissection Repair

A Critical Post-PTA Treatment for Optimized PAD Outcomes in ATK Interventions.

In This Issue

Guest Chief Medical Editors' Page

After the Meta-Analysis…

By Sabine Steiner, MD, and Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Cover Stories

Nine Months Later… An Interview With Konstantinos Katsanos, MD

Dr. Katsanos's thoughts regarding the vascular community's reaction to his group's meta-analysis, the potential influence of follow-up and adjudication variables, non-SFA applications, and what comes next.

With Konstantinos Katsanos, MSc, MD, PhD, EBIR

Panel Discussion: Exploring the Paclitaxel Safety Signal

Experts discuss considerations in trial design, adjudication, and paths forward.

With Marianne Brodmann, MD; William Gray, MD; Peter A. Schneider, MD; Ramon L. Varcoe, MBBS, MS, FRACS, PhD; and Thomas Zeller, MD, PhD

Paclitaxel Post-Panel: FDA Discusses What's Next From a Regulatory Perspective

An interview with representatives from the FDA Center for Devices and Radiological Health on the key updates to the letter to health care providers, lessons learned for future trials and follow-up protocols, and additional plans for monitoring in the future.

With Eleni Whatley, PhD, and Andrew Farb, MD

Ask the Experts: How Do You Define ‘High Risk for Restenosis'?

With Gary M. Ansel, MD; Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM; Marianne Brodmann, MD; Koen Deloose, MD; Andrew Holden, MBChB, FRANZCR, EBIR; John H. Rundback, MD; and Peter A. Schneider, MD

Understanding the Paclitaxel Dose Effect

Answers to key questions about the paclitaxel controversy, including why the dose-response effect discussion is important and the impact of improved patient-level data collection.

By Andrew Holden, MBChB, FRANZCR, EBIR

Real-World Data Collection Regarding Paclitaxel Treatment

An overview of why real-world data are pertinent to the safety assessment of paclitaxel-coated devices, with separate summaries of the projects investigating the late mortality signal via real-world data analyses.

By Anna Krawisz, MD, and Eric A. Secemsky, MD

The Natural History of Intermittent Claudication

Considering atypical presentations of symptomatic peripheral artery disease and the associated major adverse events.

By Amit N. Keswani, MD, and Joshua A. Beckman, MD

A Retrospective Look at Paclitaxel Use in the Coronary Arteries

A review of the safety and efficacy profile of paclitaxel treatment in patients with coronary artery disease.

By Mark K. Tuttle, MD, and Jeffrey J. Popma, MD

Lesion-Specific SFA Device Selection

Key questions to consider for accurate diagnoses and tailored treatment decisions.

By Koen Deloose, MD

Pipeline Report: A Look at Next-Generation SFA Technologies

A review of the recent advances in lesion crossing, atherectomy, vessel preparation, and drug delivery technologies.